Cargando…
Research progress on the mechanism of astragaloside IV in the treatment of asthma
Asthma is a common chronic respiratory disease, and its treatment is a core problem and challenge in clinical practice. Glucocorticoids (GCs) are the first-line therapy for the treatment of asthma. Local and systemic adverse reactions caused by GCs create obstacles to the treatment of asthma. Theref...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692808/ https://www.ncbi.nlm.nih.gov/pubmed/38045181 http://dx.doi.org/10.1016/j.heliyon.2023.e22149 |
_version_ | 1785153022790205440 |
---|---|
author | Yuan, Fanyi Yang, Yang Liu, Li Zhou, Pengcheng Zhu, Yi Chai, Yilu Chen, Keling Tang, Wenjun Huang, Qingsong Zhang, Chuantao |
author_facet | Yuan, Fanyi Yang, Yang Liu, Li Zhou, Pengcheng Zhu, Yi Chai, Yilu Chen, Keling Tang, Wenjun Huang, Qingsong Zhang, Chuantao |
author_sort | Yuan, Fanyi |
collection | PubMed |
description | Asthma is a common chronic respiratory disease, and its treatment is a core problem and challenge in clinical practice. Glucocorticoids (GCs) are the first-line therapy for the treatment of asthma. Local and systemic adverse reactions caused by GCs create obstacles to the treatment of asthma. Therefore, the research target is to find a new, safe, and effective therapeutic medicine at present. Natural products are an important source for treating asthma with low cost and low toxicity. Astragaloside IV (AS-IV) is an active ingredient of traditional Chinese medicine Astragalus mongholicus Bunge. Previous studies have indicated that AS-IV plays a therapeutic role in the treatment of asthma by inhibiting airway inflammation and remodeling the airway, and by regulating immunity and neuroendocrine function (Fig. 1) . It has a variety of biological characteristics such as multi-target intervention, high safety, and good curative effect. This article reviews the specific mechanism of AS-IV for the treatment of asthma to provide references for subsequent research. |
format | Online Article Text |
id | pubmed-10692808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106928082023-12-03 Research progress on the mechanism of astragaloside IV in the treatment of asthma Yuan, Fanyi Yang, Yang Liu, Li Zhou, Pengcheng Zhu, Yi Chai, Yilu Chen, Keling Tang, Wenjun Huang, Qingsong Zhang, Chuantao Heliyon Review Article Asthma is a common chronic respiratory disease, and its treatment is a core problem and challenge in clinical practice. Glucocorticoids (GCs) are the first-line therapy for the treatment of asthma. Local and systemic adverse reactions caused by GCs create obstacles to the treatment of asthma. Therefore, the research target is to find a new, safe, and effective therapeutic medicine at present. Natural products are an important source for treating asthma with low cost and low toxicity. Astragaloside IV (AS-IV) is an active ingredient of traditional Chinese medicine Astragalus mongholicus Bunge. Previous studies have indicated that AS-IV plays a therapeutic role in the treatment of asthma by inhibiting airway inflammation and remodeling the airway, and by regulating immunity and neuroendocrine function (Fig. 1) . It has a variety of biological characteristics such as multi-target intervention, high safety, and good curative effect. This article reviews the specific mechanism of AS-IV for the treatment of asthma to provide references for subsequent research. Elsevier 2023-11-10 /pmc/articles/PMC10692808/ /pubmed/38045181 http://dx.doi.org/10.1016/j.heliyon.2023.e22149 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Yuan, Fanyi Yang, Yang Liu, Li Zhou, Pengcheng Zhu, Yi Chai, Yilu Chen, Keling Tang, Wenjun Huang, Qingsong Zhang, Chuantao Research progress on the mechanism of astragaloside IV in the treatment of asthma |
title | Research progress on the mechanism of astragaloside IV in the treatment of asthma |
title_full | Research progress on the mechanism of astragaloside IV in the treatment of asthma |
title_fullStr | Research progress on the mechanism of astragaloside IV in the treatment of asthma |
title_full_unstemmed | Research progress on the mechanism of astragaloside IV in the treatment of asthma |
title_short | Research progress on the mechanism of astragaloside IV in the treatment of asthma |
title_sort | research progress on the mechanism of astragaloside iv in the treatment of asthma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692808/ https://www.ncbi.nlm.nih.gov/pubmed/38045181 http://dx.doi.org/10.1016/j.heliyon.2023.e22149 |
work_keys_str_mv | AT yuanfanyi researchprogressonthemechanismofastragalosideivinthetreatmentofasthma AT yangyang researchprogressonthemechanismofastragalosideivinthetreatmentofasthma AT liuli researchprogressonthemechanismofastragalosideivinthetreatmentofasthma AT zhoupengcheng researchprogressonthemechanismofastragalosideivinthetreatmentofasthma AT zhuyi researchprogressonthemechanismofastragalosideivinthetreatmentofasthma AT chaiyilu researchprogressonthemechanismofastragalosideivinthetreatmentofasthma AT chenkeling researchprogressonthemechanismofastragalosideivinthetreatmentofasthma AT tangwenjun researchprogressonthemechanismofastragalosideivinthetreatmentofasthma AT huangqingsong researchprogressonthemechanismofastragalosideivinthetreatmentofasthma AT zhangchuantao researchprogressonthemechanismofastragalosideivinthetreatmentofasthma |